201 related articles for article (PubMed ID: 7497577)
1. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics.
Kim DK; Kim HT; Tai JH; Cho YB; Kim TS; Kim KH; Park JG; Hong WS
Cancer Chemother Pharmacol; 1995; 37(1-2):1-6. PubMed ID: 7497577
[TBL] [Abstract][Full Text] [Related]
2. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
[TBL] [Abstract][Full Text] [Related]
4. In vitro antitumor activity of a new platinum complex, cis-malonato [(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines.
Hong WS; Kim HT; Kim KH; Kim DK
Anticancer Res; 1995; 15(1):51-4. PubMed ID: 7733640
[TBL] [Abstract][Full Text] [Related]
5. Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) .
Kim HT; Kim DK; Cho YB; Kim TS; Jung I; Kim KH; Heo DS; Bang YJ; Shin SG; Kim NK
Cancer Chemother Pharmacol; 1998; 41(2):109-16. PubMed ID: 9443623
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, tissue distribution, and excretion of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II) in dogs.
Cho YB; Kim KH; Kim DK
Drug Metab Dispos; 1995 Nov; 23(11):1280-5. PubMed ID: 8591731
[TBL] [Abstract][Full Text] [Related]
7. General pharmacology of cis-malonato[4R,5R)-4,5-bis-(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II).
Kim DK; Ahn JS; Ryu G; Kim KH; Park CW; Kim MS; Chung MH; Shin SG; Suh YH; Kim YS
Arzneimittelforschung; 1994 Sep; 44(9):1080-8. PubMed ID: 7986249
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of platinum following the administration of cis-(glycolato-O,O')[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3-dioxolane]platinum(II) in dogs.
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1997; 17(5A):3681-3. PubMed ID: 9413223
[TBL] [Abstract][Full Text] [Related]
9. A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.
Kim NK; Kim TY; Shin SG; Park YI; Lee JA; Cho YB; Kim KH; Kim DK; Heo DS; Bang YJ
Cancer; 2001 Apr; 91(8):1549-56. PubMed ID: 11301404
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of a new platinum compound, cis-(glycolato-O,O) [(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclohexane]plat inum (II) in dogs.
Kim DK; Cho YB; Kim HT; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(3A):1167-9. PubMed ID: 8702230
[TBL] [Abstract][Full Text] [Related]
11. Mammary excretion and placental transfer of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum(II) in rats.
Cho YB; Kim KH; Kim DK; Miyamoto G
Arzneimittelforschung; 1996 Sep; 46(9):926-30. PubMed ID: 8876944
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3-dioxolane]platinum(II) in rats.
Cho YB; Kim DK; Kim KH; Miyamoto G
Arzneimittelforschung; 1996 Jun; 46(6):629-34. PubMed ID: 8767356
[TBL] [Abstract][Full Text] [Related]
13. Embryotoxic effects of SKI 2053R, a new potential anticancer agent, in rats.
Chung MK; Kim JC; Roh JK
Reprod Toxicol; 1998; 12(3):375-81. PubMed ID: 9628560
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes.
Kim DK; Kim G; Gam J; Cho YB; Kim HT; Tai JH; Kim KH; Hong WS; Park JG
J Med Chem; 1994 May; 37(10):1471-85. PubMed ID: 8182706
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of five new platinum complexes having a glycolate leaving ligand.
Hong WS; Min YI; Kim HT; Cho YB; Kim KH; Kim DK
J Korean Med Sci; 1995 Aug; 10(4):269-74. PubMed ID: 8593207
[TBL] [Abstract][Full Text] [Related]
16. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma.
Kim NK; Im SA; Kim DW; Lee MH; Jung CW; Cho EK; Lee JT; Ahn JS; Heo DS; Bang YJ
Cancer; 1999 Oct; 86(7):1109-15. PubMed ID: 10506693
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
19. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
20. In vitro antitumor activity of a new platinum complex, DWA2114R against human tumor cell lines.
Akamatsu K; Saito H; Tsunenari T; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Anticancer Res; 1993; 13(6A):2261-5. PubMed ID: 8297143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
